share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  08/17 05:03

Moomoo AI 已提取核心信息

On August 15, 2024, Conduit Pharmaceuticals Inc. received two deficiency notices from The Nasdaq Stock Market LLC. The first notice indicated that the company's common stock did not meet the Nasdaq's minimum market value of publicly held shares requirement of $15 million over the past 30 consecutive business days. The second notice stated that the company also failed to comply with the minimum market value of listed securities requirement of $50 million. Conduit Pharmaceuticals has been given 180 days, until February 11, 2025, to regain compliance with both requirements. If the company fails to meet these requirements within the given timeframe, its securities may be delisted from Nasdaq. The company may also consider transferring its securities to The Nasdaq Capital Market if it meets the continued listing requirements there. In a separate event, Conduit Pharmaceuticals became aware of undisclosed share dispositions by a director through a subsidiary and a third-party pledge arrangement involving approximately 31% of its outstanding common stock. In response, the company has formed two independent committees to review these matters and determine necessary actions.
On August 15, 2024, Conduit Pharmaceuticals Inc. received two deficiency notices from The Nasdaq Stock Market LLC. The first notice indicated that the company's common stock did not meet the Nasdaq's minimum market value of publicly held shares requirement of $15 million over the past 30 consecutive business days. The second notice stated that the company also failed to comply with the minimum market value of listed securities requirement of $50 million. Conduit Pharmaceuticals has been given 180 days, until February 11, 2025, to regain compliance with both requirements. If the company fails to meet these requirements within the given timeframe, its securities may be delisted from Nasdaq. The company may also consider transferring its securities to The Nasdaq Capital Market if it meets the continued listing requirements there. In a separate event, Conduit Pharmaceuticals became aware of undisclosed share dispositions by a director through a subsidiary and a third-party pledge arrangement involving approximately 31% of its outstanding common stock. In response, the company has formed two independent committees to review these matters and determine necessary actions.
2024年8月15日，Conduit Pharmaceuticals Inc.收到了来自Nasdaq Stock Market LLC的两份不足通知。第一份通知指出公司的普通股未满足过去30个连续工作日纳斯达克公开持股要求1500万美元的最低市值。第二份通知称该公司还未满足上市证券的最低市值要求5000万美元。Conduit Pharmaceuticals有180天的时间，到2025年2月11日重新符合两项要求。如果公司未能在规定时间内满足这些要求，其证券可能从纳斯达克退市。该公司也可以考虑将其证券转移到Nasdaq Capital Market，如果满足了继续上市的要求。在另一个事件中，Conduit Pharmaceuticals注意到一名董事通过子公司和涉及约31%其未流通普通股的第三方质押安排披露未公开披露的股份。作为回应，公司已组建了两个独立的委员会审查这些事项并判断必要的行动。
2024年8月15日，Conduit Pharmaceuticals Inc.收到了来自Nasdaq Stock Market LLC的两份不足通知。第一份通知指出公司的普通股未满足过去30个连续工作日纳斯达克公开持股要求1500万美元的最低市值。第二份通知称该公司还未满足上市证券的最低市值要求5000万美元。Conduit Pharmaceuticals有180天的时间，到2025年2月11日重新符合两项要求。如果公司未能在规定时间内满足这些要求，其证券可能从纳斯达克退市。该公司也可以考虑将其证券转移到Nasdaq Capital Market，如果满足了继续上市的要求。在另一个事件中，Conduit Pharmaceuticals注意到一名董事通过子公司和涉及约31%其未流通普通股的第三方质押安排披露未公开披露的股份。作为回应，公司已组建了两个独立的委员会审查这些事项并判断必要的行动。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间